Home > Boards > US Listed > Medical - Drugs >

MEI Pharma, Inc. (MEIP)

Add MEIP Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 12/21/2018 5:58:36 PM - Followers: 84 - Board type: Free - Posts Today: 0

MEI Pharma (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor being developed in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Our clinical development pipeline also includes ME-401, a highly selective oral PI3K delta inhibitor, and ME-344, a novel mitochondrial inhibitor.


In August 2016, we announced that the U.S. Food & Drug Administration granted Breakthrough Therapy Designation for Pracinostat in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy. Later that month, we entered into an exclusive licensing, development and commercialization agreement with Helsinn Healthcare, SA, a Swiss pharmaceutical corporation, for Pracinostat in AML and other potential indications, including MDS.


ME-401 is a potent and selective oral inhibitor of PI3K delta, a molecular target that plays a critical role in the proliferation and survival of certain hematologic cancer cells. Results from a first-in-human, single ascending dose clinical study suggest that ME-401 has the potential for an improved therapeutic window compared to other PI3K delta inhibitors, with a half-life that supports once-daily dosing. A Phase Ib dose-escalation study of ME-401 in patients with recurrent chronic lymphocytic leukemia (CLL) or follicular non-Hodgkin's lymphoma (fNHL) opened for enrollment in September 2016.


ME-344 is our isoflavone-derived mitochondrial inhibitor drug candidate. Results from a Phase I clinical study of ME-344 in patients with refractory solid tumors showed evidence of clinical activity, including a confirmed partial response in a heavily pre-treated patient with small cell lung cancer who remained on study for two years. An investigator-sponsored study of ME-344 in combination with the VEGF inhibitor bevacizumab (marketed as Avastin®) in HER2-negative breast cancer opened for enrollment in August 2016.

MEI Pharma is listed on the Nasdaq Capital Market (Nasdaq: MEIP).

Financial Highlights as of September 30, 2016
- $58.9 million in cash
- No debt
- 36.8 million shares outstanding

Company website:

Company presentation:

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MEIP News: Current Report Filing (8-k) 12/03/2018 05:28:57 PM
MEIP News: Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Pres... 12/03/2018 01:32:00 PM
MEIP News: MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the ... 12/02/2018 12:00:00 PM
MEIP News: MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetocla... 12/01/2018 12:00:00 PM
MEIP News: Current Report Filing (8-k) 11/30/2018 05:43:04 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1302   H.C. Wainwright initiates MEIP with a "buy." bladerunner1717 12/21/18 05:58:36 PM
#1301   Day 2 of MEI conference data: MEI Pharma Presents ChrisInSF 12/02/18 12:33:35 PM
#1300   First of three days of data. Below is cut ChrisInSF 12/01/18 09:11:16 PM
#1299   MEIP reports 1st quarter, 2019 (Fiscal) results. Close bladerunner1717 11/09/18 12:25:13 PM
#1298   MEIP gets a partner for ME-401 in Japan bladerunner1717 11/05/18 09:33:07 AM
#1297   MEIP forms clinical collaboration with Beigene for ME-401 bladerunner1717 10/11/18 09:44:29 AM
#1296   Institutional ownership is now over 50%, up from bladerunner1717 08/17/18 04:04:18 PM
#1295   I would be more comfortable if MEIP could wiredawg 08/17/18 12:53:42 PM
#1294   Stifel doubles down on MEIP, considers ME-401 "Best-in-Class" bladerunner1717 08/15/18 01:10:42 PM
#1293   MEIP upgraded at Stifel bladerunner1717 07/27/18 10:36:47 AM
#1292   Well dang, thought we were going break & wiredawg 07/25/18 11:22:02 AM
#1291   Thx, Bladerunner, I just hope that when MC5 06/29/18 03:43:53 PM
#1290   Hey MC5, bladerunner1717 06/18/18 05:28:48 PM
#1289   I've owned this since before Dr. Gold MC5 06/18/18 03:33:05 PM
#1288   Report on MEIP from Traders News Source (whoever bladerunner1717 06/11/18 09:11:34 AM
#1287   The BULL case for MEIP. The Market bladerunner1717 06/10/18 02:31:31 PM
#1286   Nice. Glad to know that you are not KobeF 06/06/18 10:39:54 PM
#1285   * * $MEIP Video Chart 06-06-18 * * ClayTrader 06/06/18 04:58:12 PM
#1284   https://thestockcop.wordpress.com/2016/09/01/clay-trader-exposed/ money6870 06/06/18 01:23:11 PM
#1283   Great. I'm up $1,265 on the day. Thanks ClayTrader 06/06/18 12:19:03 PM
#1282   HOWS THAT SHORTING WORKING OUT FOR YOU LOL sandman44 06/06/18 12:16:22 PM
#1281   MEIP receives upgrade from Wells Fargo. Stock up bladerunner1717 06/06/18 12:11:14 PM
#1280   * * MEIP Video Chart Analysis 6-5-18 * * ClayTrader 06/05/18 05:47:50 PM
#1279   I've been waiting forever to say again, anything wiredawg 06/05/18 12:32:44 PM
#1278   MEIP presents interim analysis of Pracinostat in MDS bladerunner1717 06/04/18 02:49:55 PM
#1277   MEIP presents data on its mitochrondial inhibitor at bladerunner1717 06/04/18 02:34:04 PM
#1276   No I didn’t thanks. Mcap 70 * buckysherm 05/21/18 02:17:09 PM
#1275   Approximately 70 million shares outstanding after the recent bladerunner1717 05/21/18 02:04:38 PM
#1274   Trading for 1.5 times cash. Did I buckysherm 05/21/18 01:44:02 PM
#1273   Looks very interesting. Multiple shots on goal; buckysherm 05/21/18 12:24:47 PM
#1272   * * $MEIP Video Chart 05-15-18 * * ClayTrader 05/15/18 05:17:35 PM
#1271   MEIP up 50% in two days. Breaks bladerunner1717 05/15/18 03:30:23 PM
#1270   MEIP up 17% on the heels of a bladerunner1717 05/14/18 02:05:15 PM
#1269   MEIP initiated by Laidlaw with a "BUY." PT-$7 bladerunner1717 04/12/18 09:43:23 AM
#1268   A bit of positive news to keep us wiredawg 02/13/18 11:57:16 AM
#1267   For those that like visuals. :) wiredawg 02/08/18 02:24:58 PM
#1266   MEIP Reports 2Q18 (fiscal year) Results bladerunner1717 02/08/18 10:03:06 AM
#1265   Looks like MEIP GOING BACK DOWN TO 2 Gregoodwin 01/16/18 10:17:07 AM
#1264   MEIP's Pracinostat receives ODD from EMA. Stock up bladerunner1717 01/11/18 10:00:17 AM
#1263   Thanks, UFO. bladerunner1717 11/09/17 01:13:46 PM
#1262   Here, I Googled it myself and found the UFO 11/09/17 05:43:54 AM
#1261   I printed the entire news blip, you can UFO 11/09/17 05:26:48 AM
#1260   When did you get the report? What bladerunner1717 11/08/17 07:16:03 PM
#1259   I got that news on pay Bloomberg, can't UFO 11/08/17 05:03:34 PM
#1258   UFO, Do you have a link? bladerunner1717 11/08/17 04:00:56 PM
#1257   Mr. Street doesn't like the dilution. UFO 11/08/17 03:08:25 PM
#1256   MEIP reports 1st quarter (fiscal year) results. bladerunner1717 11/08/17 02:56:02 PM
#1255   CPXX was bought for $1.5 billion, as I bladerunner1717 10/14/17 06:16:09 PM
#1254   CPXX was bought for $30 so this could mypekeispooped 10/13/17 11:57:47 PM
#1253   I totally agree. Wish I'd waited till now MC5 10/05/17 04:22:59 PM